Bergenbio ASA - Asset Resilience Ratio

Latest as of December 2024: 89.96%

Bergenbio ASA (BGBIO) has an Asset Resilience Ratio of 89.96% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read BGBIO total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets

Nkr140.16 Million

≈ $14.75 Million USD Cash + Short-term Investments

Total Assets

Nkr155.80 Million

≈ $16.39 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Bergenbio ASA's Asset Resilience Ratio has changed over time. See Bergenbio ASA net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Bergenbio ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Bergenbio ASA stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Nkr140.16 Million	89.96%
Short-term Investments	Nkr0.00	0%
Total Liquid Assets	Nkr140.16 Million	89.96%

Asset Resilience Insights

Very High Liquidity: Bergenbio ASA maintains exceptional liquid asset reserves at 89.96% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Bergenbio ASA Industry Peers by Asset Resilience Ratio

Compare Bergenbio ASA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Argen-X F:1AE	Biotechnology	25.67%
Zhejiang Ausun Pharmaceutical Co Ltd SHG:603229	Biotechnology	0.21%
R&G PharmaStudies Co. Ltd. A SHE:301333	Biotechnology	35.96%
Shouyao Holdings (Beijing) Co. Ltd. A SHG:688197	Biotechnology	79.48%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	70.49%
Sunmax Biotechnology Co Ltd TWO:4728	Biotechnology	10.53%

Annual Asset Resilience Ratio for Bergenbio ASA (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Bergenbio ASA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	89.96%	Nkr140.16 Million ≈ $14.75 Million	Nkr155.80 Million ≈ $16.39 Million	+0.24pp
2023-12-31	89.72%	Nkr156.42 Million ≈ $16.46 Million	Nkr174.34 Million ≈ $18.35 Million	-0.74pp
2022-12-31	90.46%	Nkr150.80 Million ≈ $15.87 Million	Nkr166.71 Million ≈ $17.54 Million	-6.52pp
2021-12-31	96.98%	Nkr436.65 Million ≈ $45.95 Million	Nkr450.24 Million ≈ $47.38 Million	-0.78pp
2020-12-31	97.76%	Nkr721.64 Million ≈ $75.94 Million	Nkr738.20 Million ≈ $77.68 Million	+3.97pp
2019-12-31	93.79%	Nkr253.59 Million ≈ $26.68 Million	Nkr270.38 Million ≈ $28.45 Million	-1.35pp
2018-12-31	95.14%	Nkr360.41 Million ≈ $37.93 Million	Nkr378.83 Million ≈ $39.86 Million	-1.22pp
2017-12-31	96.36%	Nkr370.35 Million ≈ $38.97 Million	Nkr384.34 Million ≈ $40.44 Million	+3.64pp
2016-12-31	92.72%	Nkr161.82 Million ≈ $17.03 Million	Nkr174.54 Million ≈ $18.37 Million	--

pp = percentage points

About Bergenbio ASA

OL:BGBIO Norway Biotechnology

Market Cap

$7.75 Million

Nkr73.62 Million NOK

Market Cap Rank

#27467 Global

#257 in Norway

Share Price

Nkr0.47

Change (1 day)

-5.91%

52-Week Range

Nkr0.47 - Nkr2.00

All Time High

Nkr4414.96